睿智醫藥(300149.SZ):董事長WOO SWEE LIAN辭職
格隆匯11月1日丨睿智醫藥(300149.SZ)公佈,公司董事會於近日收到公司董事長WOO SWEE LIAN的書面辭職報吿,WOO SWEE LIAN因個人原因申請辭去公司董事長、董事、董事會戰略委員會主任委員職務,辭職後繼續擔任公司戰略顧問。根據《公司法》、《公司章程》的相關規定,其辭職報吿自送達公司董事會之日起生效。公司將按照法定程序,儘快完成新任董事長的選舉工作。
為保證董事會的正常運作,根據《公司法》和《公司章程》的相關規定,公司於2021年11月1日召開的第五屆董事會第八次會議審議通過《關於補選第五屆董事會非獨立董事的議案》,經董事會審核,同意提名樊世新為公司第五屆董事會非獨立董事候選人,任期自股東大會審議通過之日起至第五屆董事會屆滿時止。該事項尚須提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.